These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23665304)

  • 1. Safety of the production process of SURFACEN(®) to inactivate and remove virus.
    Sánchez Y; Noa E; Alfonso W; Dubed M; Alvarez G; Navea L; Montes de Oca N; Lobaina L; Díaz E
    Biologicals; 2013 Jul; 41(4):254-60. PubMed ID: 23665304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of viral inactivation of pseudorabies virus, encephalomyocarditis virus, bovine viral diarrhea virus and porcine parvovirus in pancreatin of porcine origin.
    Caruso C; Gobbi E; Biosa T; Andra' M; Cavallazzi U; Masoero L
    J Virol Methods; 2014 Nov; 208():79-84. PubMed ID: 25110118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of enveloped and non-enveloped viruses in the process of chemical treatment and gamma irradiation of bovine-derived grafting materials.
    Lee KI; Lee JS; Jung HH; Lee HY; Moon SH; Kang KT; Shim YB; Jang JW
    Xenotransplantation; 2012; 19(6):365-9. PubMed ID: 23198732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
    Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
    Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro interaction between SURFACEN® and surfactant protein A against Leishmania amazonensis.
    de Guevara YL; Hidalgo OB; Faure R; Fidalgo LM
    Chemotherapy; 2013; 59(4):247-50. PubMed ID: 24401208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of the clinical pulmonary surfactant Surfacen® against Leishmania amazonensis.
    Blanco O; Lugones Y; Díaz E; Monzote L
    Rev Inst Med Trop Sao Paulo; 2011; 53(4):235-8. PubMed ID: 21915470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interfacial behavior and structural properties of a clinical lung surfactant from porcine source.
    Blanco O; Cruz A; Ospina OL; López-Rodriguez E; Vázquez L; Pérez-Gil J
    Biochim Biophys Acta; 2012 Nov; 1818(11):2756-66. PubMed ID: 22771553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral safety characteristics of Flebogamma DIF, a new pasteurized, solvent-detergent treated and Planova 20 nm nanofiltered intravenous immunoglobulin.
    Caballero S; Nieto S; Gajardo R; Jorquera JI
    Biologicals; 2010 Jul; 38(4):486-93. PubMed ID: 20350815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological Safety of a Highly Purified 10% Liquid Intravenous Immunoglobulin Preparation from Human Plasma.
    Goussen C; Simoneau S; Bérend S; Jehan-Kimmel C; Bellon A; Ducloux C; You B; Paolantonacci P; Ollivier M; Burlot L; Chtourou S; Flan B
    BioDrugs; 2017 Jun; 31(3):251-261. PubMed ID: 28508264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Technical study on inactivating/removing virus in collagen sponge].
    Jiang L
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2013 Jul; 27(7):885-8. PubMed ID: 24063184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultraviolet-C irradiation for inactivation of viruses in foetal bovine serum.
    Vaidya V; Dhere R; Agnihotri S; Muley R; Patil S; Pawar A
    Vaccine; 2018 Jul; 36(29):4215-4221. PubMed ID: 29891350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Partitioning and inactivation of viruses by the caprylic acid precipitation followed by a terminal pasteurization in the manufacturing process of horse immunoglobulins.
    Mpandi M; Schmutz P; Legrand E; Duc R; Geinoz J; Henzelin-Nkubana C; Giorgia S; Clerc O; Genoud D; Weber T
    Biologicals; 2007 Oct; 35(4):335-41. PubMed ID: 17470396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral safety of C1-inhibitor NF.
    Terpstra FG; Kleijn M; Koenderman AH; Over J; van Engelenburg FA; Schuitemaker H; van 't Wout AB
    Biologicals; 2007 Jun; 35(3):173-81. PubMed ID: 17071103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of lyophilization on the infectivity of enveloped and non-enveloped viruses in bone tissue.
    Uhlenhaut C; Dörner T; Pauli G; Pruss A
    Biomaterials; 2005 Nov; 26(33):6558-64. PubMed ID: 15946737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on pathogen reduction technology for therapeutic plasma: an overview.
    Solheim BG; Seghatchian J
    Transfus Apher Sci; 2006 Aug; 35(1):83-90. PubMed ID: 16934528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral validation of the manufacturing process of high purity albumin from placentas.
    Grandgeorge M; Véron JL
    Dev Biol Stand; 1993; 81():237-44. PubMed ID: 8174808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Process changes and their effect on process evaluation for viral clearance.
    Marcus-Sekura C
    Dev Biol Stand; 1996; 88():125-30. PubMed ID: 9119123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of mouse minute virus inactivation by high temperature short time treatment technology: a statistical assessment.
    Murphy M; Quesada GM; Chen D
    Biologicals; 2011 Nov; 39(6):438-43. PubMed ID: 21985900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivation of viruses by pasteurization at 60 °C for 10 h with and without 40% glucose as stabilizer during a new manufacturing process of α2-Macroglobulin from Cohn Fraction IV.
    Huangfu C; Ma Y; Jia J; Lv M; Zhu F; Ma X; Zhao X; Zhang J
    Biologicals; 2017 Mar; 46():139-142. PubMed ID: 28215695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogen safety of a pasteurized four-factor human prothrombin complex concentrate preparation using serial 20N virus filtration.
    Nowak T; Popp B; Gröner A; Schäfer W; Kalina U; Enssle K; Roth NJ
    Transfusion; 2017 May; 57(5):1184-1191. PubMed ID: 28191640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.